MMD patients with NAFLD exhibited elevated levels of several biomarkers, including triglyceride (TG), gamma-glutamyl transpeptidase (GGT), uric acid (UA), BMI, aspartate transaminase (AST), and alanine transaminase (ALT), whereas reduced levels of HDL-C. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.